论文部分内容阅读
长期以来,细胞毒类抗肿瘤药物因毒性大,选择性低,限制了它们的临床应用。近十几年来,人们将这些药物与针对肿瘤细胞表面抗原的单克隆抗体相连接,利用抗体的特异性导向作用,将药物运载到肿瘤病灶处,增加其中的药物浓度,提高疗效,减少全身性毒性作用。但是,药物与单克隆抗体(McAb)的结合,需要特定的化学反应过程来完成,结合后的交联体,既要保持药物的活性,又要保证抗体的活性不受影响,又不增加毒副作
For a long time, cytotoxic antitumor drugs due to toxicity, low selectivity, limiting their clinical application. In the past ten years, people linked these drugs with monoclonal antibodies against tumor cell surface antigens, and used the specific guidance of antibodies to carry the drugs to the tumor lesions, increase the concentration of drugs therein, improve the curative effect and reduce the systemic Toxic effects. However, the combination of the drug with the monoclonal antibody (McAb) requires a specific chemical reaction process. The combined cross-linked product not only maintains the activity of the drug but also ensures that the activity of the antibody is not affected without increasing the toxicity Deputy